Norbert Bischofberger has been with Gilead almost since its beginning and helped the company establish dominance in HIV and hepatitis C, but leaves as it's starting to build franchises in oncology and inflammation. Gilead veterans John McHutchinson and Andrew Cheng are elevated in his place.
Gilead Sciences Inc. Executive Vice President-Research & Development and Chief Scientific Officer Norbert Bischofberger is moving on – though where he is going is not clear – after nearly three decades and the establishment of two multibillion-dollar franchises in HIV and hepatitis C.
Bischofberger leaves the R&D pipeline in the hands of two Gilead veterans as the company works to diversify its holdings:...
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
